Skip to main content

ORIGINAL RESEARCH article

Front. Oncol.
Sec. Cancer Molecular Targets and Therapeutics
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1442601
This article is part of the Research Topic Exploring Small Molecule Probes: Advancements and Applications in Pharmacological Research View all articles

Radiosynthesis and in-vitro identification of a molecular probe 131 I-FAPI targeting cancer-associated fibroblasts

Provisionally accepted
Yaxin Tian Yaxin Tian 1,2Yanghongyan Jiang Yanghongyan Jiang 3Ping Ma Ping Ma 1Xiaowei Ma Xiaowei Ma 1Liang Du Liang Du 1Fengkui Wang Fengkui Wang 1Xiaodong Yu Xiaodong Yu 1Qian Zhao Qian Zhao 1*
  • 1 General Hospital of Ningxia Medical University, Yinchuan, China
  • 2 School of Clinical Medicine, Ningxia Medical University, Yinchuan, Ningxia Hui Region, China
  • 3 First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong Province, China

The final, formatted version of the article will be published soon.

    Purpose: Fibroblast activation protein (FAP) is highly expressed in the mesenchyme of most malignant epithelial tumors, while its expression is low in normal tissues. FAP inhibitors (FAPIs) bind specifically to FAP and are used for tumor-targeted diagnosis and therapy. The aim of this study was to radiosynthesize a novel molecular probe 131 I-FAPI, and evaluate its in-vitro targeting and biological characteristics. Methods: The structurally modified FAPI was labelled with 131 I through the chloramine-T method. The radiolabeling rate was then detected by thin-layer chromatography (TLC). The stability of 131 I-FAPI was determined at PBS (room temperature) and serum (37℃). Its hydrophilicity was calculated by measuring its lipid-water partition coefficient. Pancreatic cancer PANC-1 cell line and glioma U87 cell line were cultured in vitro. Cell uptake assay was used to show the binding ability of 131 I-FAPI. The CCK-8 assay was used to calculate the inhibitory effects of 131 I-FAPI at different time points (4h, 8h, 12h, 24h, 48h) after comparing with the 131 I and FAPI. The before-and-after-24h scratch areas of the two cells were determined in order to verify the effect of 131 I-FAPI on the migration ability of the cells. Results: The radiolabeling rate was (84.9±1.02) %. The radiochemical purity of 131 I-FAPI remained over 80% in both 25℃ PBS and 37℃ serum. The value of the lipidwater partition coefficient was -0.869 ± 0.025, indicating the hydrophilic of the probe. The cellular uptake assay showed that U87 cells had a specific binding capacity for 131 I-FAPI. In cell inhibition assays, the inhibitory effect of 131 I-FAPI on U87 cells increased with time. The results of cell scratch assay showed that 131 I-FAPI had the strongest inhibitory effect on the migratory ability of U87 cells compared with 131 I and FAPI (P<0.001).Conclusions: 131 I-FAPI was synthesized with good in-vitro stability and hydrophilic properties. It can be specifically bound by U87 cells. The proliferation and migration of U87 cells can be effectively inhibited. 131 I-FAPI is promising to become a therapeutic probe.

    Keywords: cancer-associated fibroblasts1, FAPI2, molecular probe3, 131 I4, identification5

    Received: 02 Jun 2024; Accepted: 15 Aug 2024.

    Copyright: © 2024 Tian, Jiang, Ma, Ma, Du, Wang, Yu and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Qian Zhao, General Hospital of Ningxia Medical University, Yinchuan, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.